Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

For the latest in precision medicine, sign up for our monthly newsletter to be among the first to receive
exclusive insights, in-depth market analyses, and expert articles directly to your inbox

A New Golden Age for Target Identification: Accessing the Novel Druggable Space with Discovery Proteomics

On-demand webinar presented by Mo Jain, MD, PhD, Founder and CEO, Sapient and Jonathan Usuka, PhD, MBA Chief Business Officer, Sapient
Watch Now

Accelerate Protein Screening by Sequencing Protein Barcodes on Platinum®

On-demand webinar presented by Joel McDade, PhD, Sr. Commercial Business Development Manager, Quantum-Si and Bonnie Lun, PhD, Field Application Scientist
Watch Now

Challenges and Strategies for the Application of Omics and Spatial Technologies

A concise report featuring insights from the prominent thought leaders of Omics 2023 and Spatial 2024
Read Now

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Diagnostic Development

Emergency Use Authorization Issued by FDA for Mpox Virus DNA Test

EUAs exist under FDA regulation to improve the availability of medical countermeasures, such as vaccines and diagnostic tests, during public health emergencies. With future pandemics a tangible possibility, further EUAs for other PCR tests and vaccines are all but certain.
Read More
Genomic Biomarkers

Clinical Biomarker Trends to Watch in 2023

The identification of novel clinical biomarkers is set to continue, with further research and investment in fields such as next-gen sequencing and miRNA targeting.
Read More
Genome Editing

Policy Issues for Responsible Genomics Research

Responsible genomics research is vital to ensuring the advancement of health for society. But what are the ethical, social, and legal considerations that go into genomics-based decision making?
Read More
Clinical Development

Keytruda sees Trial Success in Treating Endometrial Cancer Patients

The immunotherapeutic was successfully trialled in patients with endometrial cancer, the results of which Merck said it would discuss with regulatory authorities.
Read More
Clinical Development

Eli Lilly Focus on Phase III Trial for Alzheimer’s Treatment Following FDA Fast Lane Setback

The FDA ‘specifically requested’ data from at least 100 patients who received a minimum 12 months’ treatment of Lilly’s drug donanemab before the approval process could progress further.
Read More
Clinical Diagnostics

Long-Read Sequencing Named 'Method of the Year 2022'

Powering a more complete reading of genomic information, Nature hails long-read sequencing as the omics-based method of the year.
Read More
Clinical Development

FDA Approves Merck-Developed KEYTRUDA for Non-Small Cell Lung Cancer Therapy

KEYTRUDA demonstrated a clinically meaningful improvement in disease-free survival in patients following surgical resection and platinum-based chemotherapy.
Read More
Spatial Analysis

The Future of Spatial Technology, Analysis, and Imaging

This Insight Article looks at the short and long-term predictions for spatial technological regulation, standardisation, and collaboration for the omics field.
Read More
Biomarker Discovery & Development

Bioassay Optimisation: How the Pandemic Reshaped International Standards for New Therapeutics

The global race to develop, trial, and distribute a vaccine for Covid-19 may have permanently accelerated the development of future therapeutics, including treatments for cancer.
Read More
Clinical Diagnostics

FDA Clears Genomic Profiling Test for Solid Tumours 

Regulatory approval for comprehensive genomic profiling test signifies “significant advancement in personalised cancer care.”
Read More
Genome Editing

FDA and NIH Sign Interagency Collaboration Agreement to Advance Proteogenomics Research

A memorandum of understanding has been reached between the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) to provide a framework for solving complex problems in molecular characterisation and classification of tumours.
Read More
Clinical Development

FDA Commits to Increasing Diversity in Clinical Trials

The move follows steps announced by the EMA and the MHRA to ensure clinical trials are more reflective of patient populations.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things discovery